OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial
OSE Immunotherapeutics announced it has received a second positive recommendation from an independent Data Monitoring Committee (IDMC) for its Phase 3 ARTEMIA trial evaluating Tedopi® in non-small cell lung cancer.
OSE Immunotherapeutics has received a second positive recommendation from the independent Data Monitoring Committee (IDMC) for its ongoing Phase 3 ARTEMIA trial. The trial is evaluating the efficacy of Tedopi®, the company's immuno-oncology asset, in treating non-small cell lung cancer (NSCLC).
The IDMC's recommendation allows the ARTEMIA trial to continue as planned, marking a significant step in the clinical development of Tedopi®. This immunotherapy drug is designed to activate the immune system to target and destroy cancer cells.
The ARTEMIA trial is a randomized, open-label study comparing Tedopi® in combination with chemotherapy against standard chemotherapy. It focuses on patients whose NSCLC has progressed or recurred after initial platinum-based chemotherapy.
OSE Immunotherapeutics is advancing a portfolio of advanced immunotherapies, including Tedopi® and Lusvertikimab, aiming to develop novel treatments for cancer and autoimmune diseases. Recent company updates also include progress on other clinical programs and financial reporting for fiscal year 2025.